REGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Regeneron Pharmaceuticals Inc (REGN) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock is facing significant headwinds due to recent clinical trial failures, downgrades in analyst ratings, and reduced price targets. Additionally, Congress trading data shows a cautious stance with a recent sale transaction. While hedge funds are buying, the lack of clear positive catalysts and bearish technical indicators suggest holding off on buying this stock until more favorable conditions arise.
The MACD is positive and expanding, but the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 601.246, with resistance at 633.815. This indicates a lack of strong upward momentum.
Hedge funds are increasing their positions, with a 167% increase in buying activity over the last quarter. Additionally, Regeneron has strong ongoing commercial products like Eylea and dupi, which continue to generate revenue.
Recent clinical trial failures, particularly the Phase 3 LAG-3 melanoma trial, have led to significant downgrades in analyst ratings and price targets. Congress members have also shown a cautious stance with a recent sale transaction. The broader pharmaceutical sector is under pressure due to proposed drug price negotiations.
Financial data for the latest quarter is unavailable, but analyst commentary suggests concerns over longer-term EPS growth and potential revenue downside due to biosimilar competition.
Analysts have broadly lowered their price targets, with the most recent range between $641 and $875. Several firms have downgraded the stock, citing pipeline disappointments and limited near-term catalysts. However, some analysts maintain a Buy or Overweight rating, highlighting the company's core assets and cash on hand as downside support.
